

Supplemental Table. Baseline characteristics of participants in the JUPITER trial among those with none or at least one major risk factor for diabetes (metabolic syndrome, impaired fasting glucose, HbA1c > 6 percent, or body mass index \geq 30 kg/m²); by treatment group.

Baseline Characteristic	Major Risk Factors for Diabetes			
	Rosuvastatin; N=3 065	None Placebo; N=3 030	Rosuvastatin; N=5 743	One or More Placebo; N=5 765
Age, years	66 (60-72)	66 (60-72)	66 (61-71)	66 (60-71)
Female, N (%)	1 003 (32.7)	960 (31.7)	2 394 (41.7)	2 377 (41.2)
Race/Ethnicity, N (%)				
Caucasian	2 298 (75.0)	2 246 (74.1)	3 997 (69.6)	4 013 (69.6)
Black	386 (12.6)	386 (12.7)	708 (12.3)	731 (12.7)
Hispanic	265 (8.6)	284 (9.4)	836 (14.6)	827 (14.3)
Other/unknown	116 (3.8)	114 (3.8)	202 (3.5)	194 (3.4)
Body Mass Index, kg/m ²	25.4 (23.1-27.5)	25.5 (23.2-27.5)	30.8 (27.5-34.1)	30.7 (27.5-33.8)
Hypertension, N (%)	1 408 (45.9)	1 349 (44.5)	3 613 (62.9)	3 725 (64.6)
Current Smoking, N (%)	651 (21.2)	667 (22.0)	737 (12.8)	738 (12.8)
hsCRP, mg/L				
men	3.8 (2.6-6.6)	3.9 (2.6-6.8)	4.1 (2.8-6.6)	4.2 (2.8-6.8)
women	3.8 (2.7-6.0)	3.8 (2.6-6.4)	5.0 (3.3-8.3)	5.0 (3.3-8.2)
LDL-C, mg/dL	108 (93-119)	108 (92-118)	108 (95-119)	109 (95-119)
HDL-C, mg/dL	54 (45-66)	54 (46-66)	46 (38-56)	46 (38-56)
Triglycerides, mg/dL	97 (73-127)	97 (74-128)	135 (96-193)	134 (96-192)
Total Cholesterol, mg/dL	185 (167-199)	184 (167-198)	186 (169-200)	186 (170-200)
Apo A, mg/dL	171 (151-194)	169 (150-192)	158 (141-179)	158 (141-179)
Apo B, mg/dL	104 (91-117)	104 (91-116)	112 (98-125)	112 (99-125)
Glucose, mg/dL	89 (84-94)	89 (84-94)	99 (90-105)	99 (91-106)
HbA1c, %	5.6 (5.3-5.7)	5.6 (5.4-5.7)	5.8 (5.5-6.1)	5.8 (5.5-6.1)

All values are median (interquartile range) or N (%). For hsCRP, values are based on the average of the screening and randomization visits